Jim Cramer: Lemonade Is 'Up Too Much,' This Health Care Stock Can Go Lower (UPDATED)

Editor’s Note: The story has been updated for improved clarity and readability.

On CNBC's “Mad Money Lightning Round,” Jim Cramer weighed in on stocks brought up by viewers, highlighting risks and opportunities in the market.

High Valuations Prompt Caution

Lemonade, Inc. LMND has climbed significantly, prompting Cramer to caution, “up too much… You got to let it come down.” JMP Securities' Ronald Josey echoed similar concerns, maintaining a Market Outperform rating and raising the price target from $40 to $60 on Nov. 22.

Healthcare Stocks In Focus

Cencora, Inc. COR could “go lower,” Cramer said, preferring Cardinal Health, Inc. CAH instead. Cencora has been expanding its portfolio, completing its acquisition of Retina Consultants of America on Jan. 2. The move strengthens its position in specialized healthcare.

For Novo Nordisk A/S NVO, Cramer advised caution, saying he would be “careful” with the stock. The company recently reported Phase 3 trial results for its CagriSema combination therapy, which showed promising outcomes but the stock is down over 22% in the past month.

GLP-1 Impact on Consumer Staples

Cramer pointed out challenges for PepsiCo PEP, saying it's in the “crosshairs of the GLP-1 situation.” Despite this, Piper Sandler's Mike Lavery initiated coverage on Jan. 7 with an Overweight rating and a $171 price target, reflecting optimism for PepsiCo's resilience in response to shifting consumer trends.

Price Action:

• Novo Nordisk shares fell 2% to settle at $83.34 on Tuesday.
• PepsiCo shares fell 0.6% to close at $145.40 during the session.
• Cencora shares gained 2.3% to settle at $234.24.
• Lemonade shares fell 6.3% to settle at $36.14 on Tuesday.

Read Next:

• Bank of New York Mellon Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Image: Shutterstock